E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors
Ahmad Alhuraiji,Hagop M. Kantarjian,Prajwal Boddu,Farhad Ravandi,Gautam Borthakur,Courtney D. DiNardo,Naval Daver,Tapan M. Kadia,Naveen Pemmaraju,Sherry Pierce,Guillermo Garcia-Manero,William G. Wierda,Srdan Verstovsek,Elias Jabbour,Jorge E. Cortes +14 more
TL;DR: Responses rates and survival outcomes were comparable in CP with ACA irrespective of whether chromosomal abnormalities were “major route” or other, and the presence of ACA at diagnosis should not alter treatment strategies in these patients.
Journal ArticleDOI
Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
Tapan M. Kadia,Jorge E. Cortes,Ahmad Ghorab,Farhad Ravandi,Elias Jabbour,Naval Daver,Yesid Alvarado,Maro Ohanian,Marina Konopleva,Hagop M. Kantarjian +9 more
TL;DR: This data indicates that relapse is a major source of failure in frontline AML induction but few options exist for post-CR main...
Journal ArticleDOI
Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors.
Helen T. Chifotides,Lucia Masarova,Mansour Alfayez,Naval Daver,Yesid Alvarado,Elias Jabbour,Marina Konopleva,Hagop M. Kantarjian,Keyur P. Patel,Courtney D. DiNardo,Srdan Verstovsek +10 more
TL;DR: IDH1/2-inhibitor–based combinations conferred significant clinical responses in patients with IDH1 /2-mutated post–MPN AML treated with IDh1/ 2-i combinations.
Journal ArticleDOI
Adherence to BCR-ABL inhibitors: Issues for CML therapy
TL;DR: To maximize adherence, CML treatment should be individualized to the patient and simplified as appropriate and factors that can cause nonadherence, including dose, toxicity, time from diagnosis to prescription, and the number of concomitant medications, should be addressed and monitored by the physician.
Journal ArticleDOI
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
Elias Jabbour,Susan O'Brien,Xuelin Huang,Deborah A. Thomas,Michael Rytting,Koji Sasaki,Jorge E. Cortes,Guillermo Garcia-Manero,Tapan M. Kadia,Farhad Ravandi,Sherry Pierce,Hagop M. Kantarjian +11 more
TL;DR: A subset of adult patients with ALL in whom outcome of therapy with inotuzumab ozogamicin can be differentially predicted is identified, with a high peripheral blood absolute blast count and low platelet count independently associated with a lower likelihood of achieving at least marrow CR.